Gossamer Bio's Phase 2 TORREY study meets primary endpoint; seralutinib reduces PVR in PAH

Gossamer Bio, Inc.

Phase 2 TORREY met primary endpoint: placebo-corrected PVR reduction of 96.1 dynes (14.3%, p=0.031).
Secondary endpoint 6MWD numerically favored seralutinib by 6.5 meters (not statistically significant).
In FC III patients: 21% PVR reduction (p=0.043) and 37m 6MWD improvement (p=0.048) vs placebo.
NT-proBNP reduced by 408.3 ng/L at Week 24 (p=0.0012); right heart structure/function improved.
Seralutinib well tolerated; cough most common TEAE (43% vs 38% placebo), no subdural hematomas.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.